Novavax, the American biotechnology company, announced that its Covid-19 vaccine is 100% effective in preventing the disease.

The vaccine has an overall efficacy of 90.4%.

The company’s phase three trials for their Covid-19 vaccine involved 29,960 adults across 113 sites in the United States and six sites in Mexico provided the encouraging results.

Of those who received a vaccine in the trial, only 14 cases of coronavirus were detected and Novavax has said that all of the cases resulted in a mild illness.

US health officials have given one dose of a coronavirus vaccine to 53% of the total population and of those who have fully vaccinated 43.4% of Americans, according to the Centers for Control Disease and Prevention (CDC).

In total, since January, 309 million doses have been administered across the States.

Also Read

What are the impacts of the Sinovac COVID-19 vaccine?

Sinovac Biotech, a China-based pharmaceutical firm with headquarters in Beijing, produces CoronaVac,...